Literature DB >> 21490186

Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.

Marie Desnos-Ollivier1, Olivier Moquet, Taieb Chouaki, Anne-Marie Guérin, Françoise Dromer.   

Abstract

Clavispora lusitaniae is an opportunistic human pathogen responsible for 0.6 to 2% of candidemia. This species is intrinsically susceptible to echinocandins. Nevertheless, in this study, development of echinocandin resistance in C. lusitaniae isolates was observed during caspofungin treatment. This resistance resulted from missense mutation in the echinocandin target Fks1 gene.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21490186      PMCID： PMC3122731          DOI： 10.1128/JCM.00325-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  26 in total

1.  Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.

Authors:  Sergey V Balashov; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Molecular diagnostics of clinical strains of filamentous Basidiomycetes.

Authors:  G S de Hoog; A H Gerrits van den Ende
Journal:  Mycoses       Date:  1998 May-Jun       Impact factor: 4.377

Review 3.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

Authors:  M A Pfaller; D J Diekema; D Andes; M C Arendrup; S D Brown; S R Lockhart; M Motyl; D S Perlin
Journal:  Drug Resist Updat       Date:  2011-02-24       Impact factor: 18.500

4.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors:  G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; V B Pikounis; J M Balkovec; A F Bouffard; J F Dropinski; H Rosen; H Kropp; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 7.  Colony morphology switching of Candida lusitaniae and acquisition of multidrug resistance during treatment of a renal infection in a newborn: case report and review of the literature.

Authors:  Anne Favel; Annie Michel-Nguyen; Florence Peyron; Claude Martin; Laurent Thomachot; Annick Datry; Jean-Philippe Bouchara; Svetlana Challier; Thierry Noël; Christiane Chastin; Patrick Regli
Journal:  Diagn Microbiol Infect Dis       Date:  2003-09       Impact factor: 2.803

8.  Phylogenetic relationships of human-pathogenic Cladosporium (Xylohypha) species inferred from partial LS rRNA sequences.

Authors:  F Masclaux; E Guého; G S de Hoog; R Christen
Journal:  J Med Vet Mycol       Date:  1995 Sep-Oct

9.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Authors:  Michel Laverdière; Richard G Lalonde; Jean-Guy Baril; Donald C Sheppard; Steven Park; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

10.  Clavispora, a new yeast genus of the Saccharomycetales.

Authors:  L Rodrigues de Miranda
Journal:  Antonie Van Leeuwenhoek       Date:  1979       Impact factor: 2.271
View more
  18 in total

1.  Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.

Authors:  Sandra A Asner; Stefano Giulieri; Manuel Diezi; Oscar Marchetti; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

2.  Candida lusitaniae MICs to the echinocandins are elevated but FKS-mediated resistance is rare.

Authors:  Shawn R Lockhart; Cau D Pham; Randall J Kuykendall; Carol B Bolden; Angela A Cleveland
Journal:  Diagn Microbiol Infect Dis       Date:  2015-08-28       Impact factor: 2.803

3.  Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Shawn A Messer; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-10-23       Impact factor: 5.948

4.  Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.

Authors:  Marie Desnos-Ollivier; Stéphane Bretagne; Olivier Lortholary; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2022-04-12       Impact factor: 5.938

5.  Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.

Authors:  A Forastiero; V Garcia-Gil; O Rivero-Menendez; R Garcia-Rubio; M C Monteiro; A Alastruey-Izquierdo; R Jordan; I Agorio; E Mellado
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

Review 6.  Echinocandin resistance: an emerging clinical problem?

Authors:  Maiken C Arendrup; David S Perlin
Journal:  Curr Opin Infect Dis       Date:  2014-12       Impact factor: 4.915

7.  Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.

Authors:  Michael A Pfaller; David R Andes; Daniel J Diekema; David L Horn; Annette C Reboli; Coleman Rotstein; Billy Franks; Nkechi E Azie
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

Review 8.  Emerging Threats in Antifungal-Resistant Fungal Pathogens.

Authors:  Dominique Sanglard
Journal:  Front Med (Lausanne)       Date:  2016-03-15

9.  Use of RNA-Protein Complexes for Genome Editing in Non-albicans Candida Species.

Authors:  Nora Grahl; Elora G Demers; Alex W Crocker; Deborah A Hogan
Journal:  mSphere       Date:  2017-06-21       Impact factor: 4.389

10.  Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae.

Authors:  Jing Zhang; Fitz Gerald S Silao; Ursela G Bigol; Alice Alma C Bungay; Marilou G Nicolas; Joseph Heitman; Ying-Lien Chen
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.